Cargando…
Beyond Antibodies: The DARPin(®) Drug Platform
The DARPin(®) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows fo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312107/ https://www.ncbi.nlm.nih.gov/pubmed/32583318 http://dx.doi.org/10.1007/s40259-020-00429-8 |
_version_ | 1783549658465828864 |
---|---|
author | Stumpp, Michael T. Dawson, Keith M. Binz, H. Kaspar |
author_facet | Stumpp, Michael T. Dawson, Keith M. Binz, H. Kaspar |
author_sort | Stumpp, Michael T. |
collection | PubMed |
description | The DARPin(®) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows for the generation of diverse, well-behaved, multifunctional drug candidates. Recent clinical data illustrate the favorable safety profile of the first DARPin(®) molecules tested in patients. With the positive phase III results of the most advanced DARPin(®) drug candidate, abicipar, the DARPin(®) drug platform is potentially about to achieve its first marketing approval. This review highlights some of the key milestones and decisions encountered when transforming the DARPin(®) platform from an academic concept to a biotech drug pipeline engine. |
format | Online Article Text |
id | pubmed-7312107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73121072020-06-24 Beyond Antibodies: The DARPin(®) Drug Platform Stumpp, Michael T. Dawson, Keith M. Binz, H. Kaspar BioDrugs Review Article The DARPin(®) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows for the generation of diverse, well-behaved, multifunctional drug candidates. Recent clinical data illustrate the favorable safety profile of the first DARPin(®) molecules tested in patients. With the positive phase III results of the most advanced DARPin(®) drug candidate, abicipar, the DARPin(®) drug platform is potentially about to achieve its first marketing approval. This review highlights some of the key milestones and decisions encountered when transforming the DARPin(®) platform from an academic concept to a biotech drug pipeline engine. Springer International Publishing 2020-06-24 2020 /pmc/articles/PMC7312107/ /pubmed/32583318 http://dx.doi.org/10.1007/s40259-020-00429-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Article Stumpp, Michael T. Dawson, Keith M. Binz, H. Kaspar Beyond Antibodies: The DARPin(®) Drug Platform |
title | Beyond Antibodies: The DARPin(®) Drug Platform |
title_full | Beyond Antibodies: The DARPin(®) Drug Platform |
title_fullStr | Beyond Antibodies: The DARPin(®) Drug Platform |
title_full_unstemmed | Beyond Antibodies: The DARPin(®) Drug Platform |
title_short | Beyond Antibodies: The DARPin(®) Drug Platform |
title_sort | beyond antibodies: the darpin(®) drug platform |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312107/ https://www.ncbi.nlm.nih.gov/pubmed/32583318 http://dx.doi.org/10.1007/s40259-020-00429-8 |
work_keys_str_mv | AT stumppmichaelt beyondantibodiesthedarpindrugplatform AT dawsonkeithm beyondantibodiesthedarpindrugplatform AT binzhkaspar beyondantibodiesthedarpindrugplatform |